Skip to main content
Premium Trial:

Request an Annual Quote

Structural Genomix Raises $45M in Private Placement

NEW YORK, Sept 20 – Structural Genomix of San Diego, Calif., said Wednesday it raised $45 million in a private equity financing, bringing the amount of money the company has raised this year to $77 million.

BA Venture Partners led the round while Amerindo, MDS Health Ventures, Orbimed Advisors, and Vector Fund Management also invested in Structural Genomix, a company involved in determining protein structures.

Previous investors, including Atlas Ventures, Apple Tree Partners, Prospect Venture Partners, The Sprout Group, Index Ventures, and Vulcan Northwest, also participated in the latest round of financing.

Structural Genomix said in a statement it would use the financing to build its technology platform, which uses X-ray crystallography to transform DNA sequences into three-dimensional protein structures. The company hopes to sell its information regarding protein structures to pharmaceutical and biotechnology companies involved in developing drugs and vaccines.

In July, the company signed a memorandum of understanding with the U.S. Department of Energy’s Advanced Photon Source to build a dual undulator beamline facility, which would provide the company with access to intense X-rays beams from the DOE’s synchrotron radiation source.

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.